Published in Proc Natl Acad Sci U S A on September 23, 2002
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev (2003) 9.58
ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev (2004) 9.54
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol (2008) 5.55
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A (2004) 5.16
Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol (2004) 4.70
Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem (2010) 3.45
Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol (2006) 3.33
Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev (2013) 3.21
Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol (2008) 3.07
The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. Mol Cell (2013) 2.79
Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med (2011) 2.67
Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev (2005) 2.56
Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol (2005) 2.47
Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J Cell Biol (2003) 2.38
Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol (2004) 2.37
Tuberous sclerosis complex proteins control axon formation. Genes Dev (2008) 2.33
Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab (2009) 2.27
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A (2005) 2.23
Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One (2009) 2.20
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
Protein interactome reveals converging molecular pathways among autism disorders. Sci Transl Med (2011) 2.04
Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia (2009) 1.98
Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci U S A (2008) 1.97
mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem (2009) 1.93
Human cytomegalovirus protein UL38 inhibits host cell stress responses by antagonizing the tuberous sclerosis protein complex. Cell Host Microbe (2008) 1.85
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A (2004) 1.82
Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol (2005) 1.78
Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab (2010) 1.77
The Sestrins interact with GATOR2 to negatively regulate the amino-acid-sensing pathway upstream of mTORC1. Cell Rep (2014) 1.72
Inorganic polyphosphate stimulates mammalian TOR, a kinase involved in the proliferation of mammary cancer cells. Proc Natl Acad Sci U S A (2003) 1.71
Nutrient signaling to mTOR and cell growth. Trends Biochem Sci (2013) 1.68
AMPKα1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling. J Leukoc Biol (2013) 1.65
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol (2009) 1.61
Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev (2008) 1.60
Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J Neurosci (2011) 1.60
The TSC-mTOR pathway regulates macrophage polarization. Nat Commun (2013) 1.57
Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol (2004) 1.55
Regulation of mTORC1 by PI3K signaling. Trends Cell Biol (2015) 1.54
Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. J Biol Chem (2009) 1.53
PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB complex. Mol Cell Biol (2008) 1.53
Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet (2010) 1.53
Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab Invest (2010) 1.52
Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves. J Biol Chem (2010) 1.52
Rapamycin and mTOR kinase inhibitors. J Chem Biol (2008) 1.51
Leucine stimulates protein synthesis in skeletal muscle of neonatal pigs by enhancing mTORC1 activation. Am J Physiol Endocrinol Metab (2008) 1.49
Exercise-induced alterations in extracellular signal-regulated kinase 1/2 and mammalian target of rapamycin (mTOR) signalling to regulatory mechanisms of mRNA translation in mouse muscle. J Physiol (2006) 1.48
Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res (2009) 1.41
mTOR signaling for biological control and cancer. J Cell Physiol (2013) 1.40
Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology (2010) 1.39
Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol (2010) 1.38
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther (2008) 1.38
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther (2008) 1.36
Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best Pract Res Clin Endocrinol Metab (2010) 1.35
Regulation of T-cell survival and mitochondrial homeostasis by TSC1. Eur J Immunol (2011) 1.34
The complexes of mammalian target of rapamycin. Curr Protein Pept Sci (2010) 1.33
Growing knowledge of the mTOR signaling network. Semin Cell Dev Biol (2014) 1.33
Nutrient-sensing mechanisms across evolution. Cell (2015) 1.30
Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res (2007) 1.29
Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death. Free Radic Biol Med (2010) 1.28
Staying alive: metabolic adaptations to quiescence. Cell Cycle (2012) 1.28
Regulation of leucine uptake by tor1+ in Schizosaccharomyces pombe is sensitive to rapamycin. Genetics (2004) 1.28
PTEN represses RNA Polymerase I transcription by disrupting the SL1 complex. Mol Cell Biol (2005) 1.27
Updates of mTOR inhibitors. Anticancer Agents Med Chem (2010) 1.27
The natural history and treatment of epilepsy in a murine model of tuberous sclerosis. Epilepsia (2007) 1.26
Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol Cell Biol (2009) 1.25
Airway smooth muscle growth in asthma: proliferation, hypertrophy, and migration. Proc Am Thorac Soc (2008) 1.23
mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol (2007) 1.22
ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Signal (2010) 1.22
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22
Insulin-induced Drosophila S6 kinase activation requires phosphoinositide 3-kinase and protein kinase B. Biochem J (2003) 1.21
mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol Cell Biol (2011) 1.19
mTOR signaling and its roles in normal and abnormal brain development. Front Mol Neurosci (2014) 1.19
mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation. J Clin Invest (2015) 1.18
Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res (2008) 1.15
Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J Biol Chem (2010) 1.15
mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr (2010) 1.13
mTOR signaling contributes to chondrocyte differentiation. Dev Dyn (2008) 1.12
Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway. Am J Physiol Cell Physiol (2010) 1.12
Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neurosci Lett (2011) 1.12
Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle. Hum Mol Genet (2009) 1.11
Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer (2011) 1.10
Genetics and molecular biology of tuberous sclerosis complex. Curr Genomics (2008) 1.08
Amino acids as regulators of gene expression. Nutr Metab (Lond) (2004) 1.07
Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis. EMBO Mol Med (2011) 1.07
Multiple amino acid sensing inputs to mTORC1. Cell Res (2015) 1.06
mTOR signaling in tumorigenesis. Biochim Biophys Acta (2014) 1.06
Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation. Oncogene (2010) 1.05
PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth. Mol Cell Biol (2011) 1.05
Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed J (2013) 1.03
Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint. Mol Cell Biol (2011) 1.02
Autophagy and polyglutamine diseases. Prog Neurobiol (2011) 1.02
Insulin receptor substrate-2 mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta. Cancer Res (2009) 1.01
Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor. Am J Pathol (2005) 1.00
Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr (2010) 0.99
Regulation of mTOR by amino acids and resistance exercise in skeletal muscle. Eur J Appl Physiol (2005) 0.98
Leucine signaling in the pathogenesis of type 2 diabetes and obesity. World J Diabetes (2012) 0.98
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
TOR, a central controller of cell growth. Cell (2000) 10.41
Regulation of translation initiation by FRAP/mTOR. Genes Dev (2001) 9.40
Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem (1998) 9.37
Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell (1992) 8.51
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev (2002) 8.31
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature (1990) 7.74
A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet (2002) 7.12
Mammalian TOR: a homeostatic ATP sensor. Science (2001) 6.41
Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev (2000) 5.53
Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell (2001) 4.98
The mRNA 5' cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol (1998) 4.84
TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev (2001) 4.68
Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem (2002) 4.19
Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev (2000) 4.05
Identification of a conserved motif required for mTOR signaling. Curr Biol (2002) 3.78
Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet (1998) 3.54
Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet (1994) 2.93
Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res (2002) 2.37
Ribosomal S6 kinase 1 (RSK1) activation requires signals dependent on and independent of the MAP kinase ERK. Curr Biol (1999) 2.29
Amino acid-dependent control of p70(s6k). Involvement of tRNA aminoacylation in the regulation. J Biol Chem (1999) 2.08
The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene (1996) 2.04
Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res (1998) 2.04
The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum Mol Genet (1994) 1.81
Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway. J Biol Chem (2000) 1.68
Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes. J Biol Chem (1998) 1.54
Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem (1997) 1.42
TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum Mol Genet (2001) 1.31
Role of phosphatidylinositol-3-kinase in insulin receptor signaling: studies with inhibitor, LY294002. Biochem Biophys Res Commun (1994) 1.19
The TSC1 gene product, hamartin, negatively regulates cell proliferation. Hum Mol Genet (2000) 0.98
Interplay between insulin and nutrients in the regulation of translation factors. Biochem Soc Trans (2001) 0.90
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res (2003) 15.74
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A (2004) 10.78
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature (2008) 9.77
ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev (2004) 9.54
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev (2002) 8.31
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 7.92
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 7.88
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell (2003) 7.04
Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science (2003) 6.97
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A (2008) 6.84
mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell (2005) 6.71
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol (2002) 6.05
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest (2003) 6.04
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (2011) 5.73
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science (2011) 5.72
A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat Cell Biol (2002) 5.58
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol (2004) 5.46
Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science (2010) 5.44
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A (2004) 5.16
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med (2008) 5.15
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
A rapid method for determining protein kinase phosphorylation specificity. Nat Methods (2004) 5.04
The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol (2008) 4.92
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45
Protein sequences from mastodon and Tyrannosaurus rex revealed by mass spectrometry. Science (2007) 4.41
A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem (2002) 4.19
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell (2010) 4.07
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci (2005) 4.00
MAPK signal specificity: the right place at the right time. Trends Biochem Sci (2006) 3.96
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet (2005) 3.94
Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell (2008) 3.91
Rheb fills a GAP between TSC and TOR. Trends Biochem Sci (2003) 3.90
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci (2011) 3.89
Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol (2005) 3.89
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J (2012) 3.82
Identification of a conserved motif required for mTOR signaling. Curr Biol (2002) 3.78
Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science (2003) 3.70
Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol (2002) 3.68
Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci (2008) 3.64
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol (2004) 3.54
A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci (2007) 3.51
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol (2008) 3.50
SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell (2008) 3.43
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol (2012) 3.40
Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol (2002) 3.37
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2009) 3.35
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol (2009) 3.32
S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell (2006) 3.25
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25